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Introduction
Erythropoiesis and iron metabolism are tightly linked and inadequate iron supply to developing erythrocytes results in anemia, a condition affecting a large segment of the world's population. The coordination between erythropoietic activity and iron homeostasis is provided by hepcidin, which controls body iron balance by negatively regulating the activity of the iron exporter, ferroportin 1,2 . Hepcidin expression is inhibited by iron deficiency and high erythropoietic activity 1,2 , a response that increases iron availability to meet iron needs for hemoglobin (Hb) synthesis. Accordingly, we and others have demonstrated that recombinant human erythropoietin (rhEpo) administration to healthy humans is followed by a prompt hepcidin down-regulation [3] [4] [5] . The identification and characterization of erythroferrone (ERFE), a hepcidin-inhibiting factor produced by erythroblasts in response to Epo, provided an additional link between erythropoietic activity and iron homeostasis 6 .
Mouse studies established that ERFE synthesized in response to Epo impairs hepcidin transcription by inhibiting hepatic BMP/SMAD signaling 6, 7 . The development of a validated assay for human ERFE allowed to show that ERFE is increased in patients with β -thalassemia and in response to blood donation or administration of high doses of rhEpo 8 . Moreover, serum ERFE levels are elevated in patients with chronic kidney disease (CKD) treated with rhEpo 9 and in children affected by iron deficiency anemia 10 . However, another study did not find increased ERFE levels in CKD patients 11 . In addition, ERFE did not change in patients with reduced erythropoiesis caused by androgen deprivation therapy 12 or athletes exposed to altitude 13 and, unexpectedly, decreased in parallel with hepcidin in subjects experiencing Hb mass expansion due to altitude exposure 14 .
Therefore, the effect of accelerated erythropoiesis on ERFE in humans remains uncertain. Here, we tested the hypothesis that in healthy humans, ERFE is a physiologic erythroid regulator, i.e. responds to moderate erythropoietic stimulation, such as very low rhEpo doses or high altitude exposure.
Methods
Details of the methods are available in Supplementary material.
Study design: for the rhEpo study, Hb mass , indices of iron homeostasis and hematological parameters were repeatedly measured in 24 healthy males receiving six injections (every second/third day) of saline (placebo), rhEpo 20 UI.kg -1 (micro-dose) or rhEpo 50 UI.kg -1 (low-dose)
Written informed consent to participation in the study was provided by all subjects. The study (NCT03276910) was approved by the French ethics committee (CPP Est-III, EudraCT 2017-000375-82). For the high-altitude study, iron parameters were determined in 22 healthy subjects exposed to high altitude (3800 m) for 15 hours. Written informed consent to participation in the study was provided by all subjects. The study (NCT02778659) was approved by the French ethics committee (CPP Sud-Est-III, EudraCT 2015-004512-38).
Results
Three days after the last rhEpo injection, Hb mass was higher in subjects treated with rhEpo low-dose than those receiving placebo ( Fig 1A) . In contrast, treatment with rhEpo micro-doses did not induce significantly higher Hb mass levels in comparison to placebo treatment. Hb mass was not significantly altered following placebo treatment but nonetheless tended to decrease, possibly because of frequent blood sampling. Short treatment duration may otherwise explain the marginal change of Hb mass following rhEpo micro-doses. Unlike Hb mass , Hb concentration and hematocrit progressively increased with both rhEpo doses (Fig 2A and 2B ). As expected, circulating Epo levels increased after each injection, but rapidly declined, in particular after micro-dose treatment ( Fig 1B) . ERFE levels showed a significant dose-related increase after each injection, remaining above placebo levels up to 48 (micro-dose) or 72 hours (low-dose) and decreasing thereafter ( Fig 1C) . Following low-dose rhEpo, ERFE reached levels similar to those found in patients with anemia induced by bleeding (see Supplementary material, Analyses section). The ERFE variation pattern mirrored that of serum Epo ( Fig 3A) . Conversely, serum hepcidin decreased when Epo and ERFE rose, independently of the dose, and remained low as long as Epo and ERFE were above baseline values ( Fig 1D) . Both ERFE and hepcidin returned to placebo levels one week after the last injection.
Interestingly, there was no cumulative effect of repeated rhEpo injections on ERFE levels (Fig. 1C ).
Consistent with previous studies [3] [4] [5] , the decrease in serum ferritin with rhEpo was progressive ( Fig.   2C ). In contrast, transferrin saturation (Tfsat) was not significantly altered by rhEpo injections ( Fig   2D) .
We also found concomitant increases in Epo and ERFE in healthy subjects exposed to a high altitude condition associated with O 2 saturation of 85 ± 3% ( Fig 4A and 4B) . The correlation between ERFE and serum Epo found at high altitude ( Fig 3B) and with rhEpo treatment ( Fig 3A) suggests that hypoxia-related signaling is not directly involved in ERFE induction, as previously shown in mice 6 . ERFE tended to increase more with rhEpo micro-dose than with high altitude (P = 0.22), whereas Epo increased less with micro-dose than with high altitude (P = 0.04) (result not shown). We speculate that the shorter time of exposure to elevated Epo levels at high altitude (15 h) versus micro-dose (24 h) may account for the observed trend. Tfsat, which was close to the level defining iron deficiency (<20%), did not change ( Fig 4C) . Consistent with the low Tfsat, hepcidin concentration at sea level was below the detection limit in 15 subjects and was unchanged after exposure to high altitude in the subjects with detectable baseline values ( Fig 4D) . Lack of correlation between ERFE and hepcidin was previously found in CKD patients, in which increased ERFE levels were not accompanied by lower hepcidin 9 . In line with a previous report showing unaltered iron availability and no signs of inflammation at high altitude, 15 the inflammatory marker IL-6 was not affected by high altitude (1.28 ± 1.04 pg.mL -1 , vs. 1.25 ± 0.9 pg.mL -1 at sea level),
whereas ferritin concentration showed a small increase (from 125 ± 8 to 132 ± 7 ng.mL -1 ), nonetheless remaining within the normal range ( Fig 4E) .
Discussion
Recently, mouse studies have shown that acute rhEpo treatment down-regulates hepcidin in an ERFE-independent manner by decreasing serum iron and Tfsat 16, 17 . Moreover, the demonstration that rhEpo administration down-regulates hepcidin also in mice lacking ERFE 18 suggests that prolonged erythropoietic stimulation inhibits hepcidin expression in mice by depleting iron stores,
whereas ERFE represents an acute regulator of stress erythropoiesis 18 . Conversely, the present results show that in healthy humans ERFE responds even to low Epo levels which are not associated with Hb mass expansion, a functional marker of erythropoietic response 19 . This conclusion is also supported by our findings in a physiological condition such as high-altitude hypoxia (Fig 4) .
Furthermore, our data showing no alterations in Tfsat and a progressive decrease in ferritin with repeated rhEpo injections are consistent with the view that ERFE may inhibit hepcidin transcription directly in the absence of changes i n serum and liver iron 7 . In fact, the ERFE-hepcidin axis was affected early, i.e. 24 hours after the first rhEpo injection, while other serum iron parameters were unchanged at that time, as t test analysis showed no difference in ferritin between groups at 24 and 48 hours after the first injection (see Supplementary material, Statistical analysis section). However, it is well conceivable that under conditions of strong erythropoietic stimulation, such as in mice treated with high doses of rhEpo (8000 UI.kg -1 ) [16] [17] [18] , increased iron consumption for erythropoiesis leads to iron depletion and hepcidin repression.
The introduction of the Athlete's Blood Passport (ABP) 20 has improved blood doping detection, although also the ABP has several limitations 21 , in particular detecting micro-dose rhEpo doping 22 .
A study in which ERFE was measured in 6 subjects receiving intravenously or subcutaneously relatively high doses of rhEpo or analogs, using an assay different from the one used in this study did not suggest ERFE as a reliable marker for rhEpo doping 23 , although (while our manuscript was under revision) the same group reported that a different ELISA assay was able to detect increased 6 ERFE levels in the same samples 24 . Conversely, increased erythropoiesis induced by training did not affect ERFE and hepcidin levels in runners 25 . Our results demonstrate that ERFE is sensitive enough to flag even micro-dose rhEpo, correlates with Epo levels (see Fig 3A and 3B) and has a detection window longer than that of Epo, thereby indicating that ERFE holds promise as a novel anti-doping biomarker for ABP implementation, although additional studies are required. In view of our results, ferritin or hepcidin could also be considered as potential micro-dose rhEpo biomarkers, however both factors may be confounded by iron supplementation, a legal practice commonly used by athletes.
In summary, the present results demonstrate that in healthy humans ERFE is promptly enhanced in response to moderately increased Epo levels and represses hepcidin in an iron-independent way.
ERFE determination may provide additional analytical support for the fight against doping. 
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Analyses
Hb concentration (Hb) and hematocrit (Hct) were assessed on whole blood with a XN Series analyzer (Sysmex).
Serum was stored at -80°C and ERFE levels were determined using an ELISA assay (Intrinsic LifeSci.) that detects ERFE in a standard range 0.16-10 ng.mL -1 and has been validated with clinically relevant human samples 3 . To further validate this assay, we measured serum ERFE S2 concentration in 3 patients with anemia induced by bleeding (Hb concentration 96 ± 0.6 g.L -1 ). In line with previous findings showing a 3-4-fold increase of ERFE in blood donors 3 , we found that ERFE levels were 3.7 ± 1.4 ng.mL -1 during anemia induced by bleeding, as compared to the mean concentration of 0.7 ± 1.2 ng.mL -1 determined at baseline in the healthy subjects examined in the present studies 1 and 2. Of note, ERFE after low-dose rhEpo reached levels of 3.6 ± 1.3 ng.mL -1 , similar to those observed during anemia induced by bleeding.
The other proteins were evaluated using commercially available ELISA for Epo (Quantikine, R&D Systems), IL-6 (high sensitivity, eBioscience), ferritin (Architect Ferritin, Abbott, IL). Serum iron was assessed by FerroZine colorimetry, transferrin was measured by nephelometry with N latex human transferrin and transferrin saturation (Tfsat) was calculated. Serum hepcidin was measured by SELDI-TOF mass spectrometry as described elsewhere 4 .
Statistical analysis
Reported values are means ± SD. Statistics were performed with SPSS ® (version 22.0, IBM Corp, Armonk, NY). In study 1, Hbmass data were analyzed using a two-way repeated measure ANOVA (time × treatment) with the Bonferroni's method for pairwise comparisons. Mixed effects models were used to compare Epo, ERFE, hepcidin, Hb, Hct, ferritin, and Tfsat between groups at the different time points (study 1). Data were ln transformed to meet the conditions of applications of parametric tests, when needed. The group was included as a fixed factor, and baseline levels of these parameters were used as a covariate. We also tested the occurrence (one to four occurrences, depending on the time point considered) to assess the cumulative effect of repeated rhEpo injections, as well as the group × occurrence interaction. Since there was a strong cumulative effect on ferritin (see Fig 2C) UI.kg -1 : 259 ± 69; Epo 50 UI.kg -1 : 313 ± 105; P = 0.37). In study 2, data were analyzed using a one-
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way repeated measure ANOVA. For both studies, the relationship between two quantitative parameters was examined by linear regression. Unpaired t tests were performed on ln-transformed data to compare the effects of single rhEpo micro-dose injection (at 24 h) versus high-altitude exposure on ERFE and Epo increases. A P value of < .05 was considered significant. 
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